AP2005003262A0 - Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors. - Google Patents

Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors.

Info

Publication number
AP2005003262A0
AP2005003262A0 AP2005003262A AP2005003262A AP2005003262A0 AP 2005003262 A0 AP2005003262 A0 AP 2005003262A0 AP 2005003262 A AP2005003262 A AP 2005003262A AP 2005003262 A AP2005003262 A AP 2005003262A AP 2005003262 A0 AP2005003262 A0 AP 2005003262A0
Authority
AP
ARIPO
Prior art keywords
tgf
inhibitors
growth factor
isoxazole compounds
tranforming growth
Prior art date
Application number
AP2005003262A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2005003262A0 publication Critical patent/AP2005003262A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2005003262A 2002-09-18 2003-09-12 Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors. AP2005003262A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41213102P 2002-09-18 2002-09-18
US48458003P 2003-07-02 2003-07-02
PCT/IB2003/004005 WO2004026865A1 (en) 2002-09-18 2003-09-12 Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
AP2005003262A0 true AP2005003262A0 (en) 2005-03-31

Family

ID=32033584

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003262A AP2005003262A0 (en) 2002-09-18 2003-09-12 Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors.

Country Status (25)

Country Link
US (1) US7030125B2 (xx)
EP (1) EP1542995A1 (xx)
JP (1) JP2006506443A (xx)
KR (1) KR20050057441A (xx)
CN (1) CN1681809A (xx)
AP (1) AP2005003262A0 (xx)
AR (1) AR041275A1 (xx)
AU (1) AU2003263431A1 (xx)
BR (1) BR0314286A (xx)
CA (1) CA2499332A1 (xx)
CO (1) CO5550458A2 (xx)
EA (1) EA200500286A1 (xx)
EC (1) ECSP055685A (xx)
HR (1) HRP20050246A2 (xx)
IS (1) IS7695A (xx)
MA (1) MA27444A1 (xx)
MX (1) MXPA05002378A (xx)
NO (1) NO20051852L (xx)
OA (1) OA12925A (xx)
PA (1) PA8583101A1 (xx)
PE (1) PE20050076A1 (xx)
PL (1) PL375973A1 (xx)
TW (1) TW200410954A (xx)
UY (1) UY27983A1 (xx)
WO (1) WO2004026865A1 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2005003264A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
PL375979A1 (en) * 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
AP2005003261A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors.
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007009888A (es) 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CA2629432A1 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
NZ713219A (en) 2013-03-14 2017-04-28 Massachusetts Inst Technology Compositions and methods for epithelial stem cell expansion and culture
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
KR102493376B1 (ko) 2014-09-03 2023-01-27 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
EP3906233B1 (en) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5095272A (xx) * 1973-12-24 1975-07-29
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US5932576A (en) 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1349851A4 (en) 2000-11-16 2004-09-08 Smithkline Beecham Corp COMPOUNDS
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
ES2237671T3 (es) * 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ グループ リミテッド Tgf阻害剤としてのピラゾール
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento

Also Published As

Publication number Publication date
EA200500286A1 (ru) 2005-08-25
CN1681809A (zh) 2005-10-12
OA12925A (en) 2006-10-13
EP1542995A1 (en) 2005-06-22
US7030125B2 (en) 2006-04-18
IS7695A (is) 2005-02-14
BR0314286A (pt) 2005-08-02
NO20051852L (no) 2005-06-16
MXPA05002378A (es) 2005-05-23
US20040116473A1 (en) 2004-06-17
PL375973A1 (en) 2005-12-12
MA27444A1 (fr) 2005-07-01
CO5550458A2 (es) 2005-08-31
AR041275A1 (es) 2005-05-11
KR20050057441A (ko) 2005-06-16
CA2499332A1 (en) 2004-04-01
AU2003263431A1 (en) 2004-04-08
TW200410954A (en) 2004-07-01
ECSP055685A (es) 2005-05-30
HRP20050246A2 (en) 2005-10-31
JP2006506443A (ja) 2006-02-23
PA8583101A1 (es) 2004-04-23
UY27983A1 (es) 2004-04-30
WO2004026865A1 (en) 2004-04-01
PE20050076A1 (es) 2005-03-26

Similar Documents

Publication Publication Date Title
AP2005003262A0 (en) Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors.
AP2005003261A0 (en) Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors.
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
MXPA03004794A (es) Derivados de acido mandelico y su uso como inhibidores de trombina.
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
HUP0301248A3 (en) Thiadiazole and oxadiazole derivatives, their use as phosphodiesterase-7 inhibitors
IL200471A0 (en) Spinosyn-producing polyketide synthases
EP1391502A4 (en) HOST MICROORGANISMS
AP2005003263A0 (en) Pyrazole derivatives as transforming growth factor(TGF) inhibitors.
PL358673A1 (en) Piperidine coumpounds for use as ccr-3 inhibitors
AU2003284399A1 (en) Plk inhibitors
GB9907683D0 (en) Substituted azetidin-2-ones as cysteine protease inhibitors
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AU2003230392A1 (en) Beta-secretase inhibitors
AU2002950316A0 (en) Plant growth medium
AU2001275085A1 (en) Methods, compounds and compositions for treating gout
AU2002344514A1 (en) A natural compound useful for treating diabetes, its preparation and use
AU2001249074A1 (en) Human hepatocyte growth factor activator inhibitor homologue
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
HK1057900A1 (en) 2-Aminothiazoline derivatives and their use as no-synthase inhibitors.
EP1437142A4 (en) MEANS OF INHIBITING CELL GROWTH
ZA200205222B (en) Crystal growth.
EG24687A (en) Coal-based organic growth compound